Everolimus (RAD001) and anti-angiogenic cyclophosphamide show long-term control of gastric cancer growth in vivo.

Cejka, Daniel

Everolimus (RAD001) and anti-angiogenic cyclophosphamide show long-term control of gastric cancer growth in vivo. [electronic resource] - Cancer biology & therapy Sep 2008 - 1377-85 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

1555-8576

10.4161/cbt.7.9.6416 doi


Angiogenesis Inhibitors--pharmacology
Animals
Antineoplastic Agents--pharmacology
Caspase 3--metabolism
Cell Line, Tumor
Cell Proliferation--drug effects
Cyclophosphamide--pharmacology
Drug Therapy, Combination
Enzyme Activation--drug effects
Everolimus
Female
Humans
Immunohistochemistry
Ki-67 Antigen--metabolism
Mice
Mice, SCID
Necrosis--pathology
Neovascularization, Pathologic--drug therapy
Random Allocation
Sirolimus--analogs & derivatives
Stomach Neoplasms--blood supply
Tumor Burden--drug effects
Xenograft Model Antitumor Assays--methods